Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar 14;45(1):96.
doi: 10.1007/s10792-025-03480-y.

Predictors of macular edema recurrence and visual outcomes in branch retinal vein occlusion treated with aflibercept or ranibizumab

Jung-Tzu Chang  1 , Hsiang-Wen Chien  1   2   3   4 , Yi-Ting Hsieh  5   6 , Kwan-Rong Liu  1 , Po-Cheng Kuo  1   4 , Cheng-Lien Ho  1 , Chu-Hsuan Huang  7   8   9
Affiliations

Predictors of macular edema recurrence and visual outcomes in branch retinal vein occlusion treated with aflibercept or ranibizumab

Jung-Tzu Chang et al. Int Ophthalmol. .

Abstract

Purpose: To investigate the risk factors for visual outcomes and recurrence of macular edema (ME) in branch retinal vein occlusion (BRVO) after intravitreal injection (IVI) of anti-vascular endothelial growth factor (anti-VEGF) agents.

Methods: Thirty eyes of 30 patients with recent-onset, treatment naive BRVO with ME receiving IVI aflibercept and ranibizumab in a tertiary care hospital were enrolled retrospectively. Treatment response was classified into "responsive group" and "recurrent/refractory group" by absence or presence of ME after consecutive monthly IVI anti-VEGF therapy. The correlation between the optical coherent tomography and fluorescein angiography features and treatment response was analyzed during a 1-year follow-up period.

Results: In thirty eyes, the logarithm of the minimum angle of resolution best-corrected visual acuity (BCVA) improved from 0.69 ± 0.39 to 0.55 ± 0.48, and was comparable in the responsive and recurrent/refractory groups (p = 0.683). At baseline, the recurrent group had a higher prevalence of subretinal fluid (SRF), disruption in the ellipsoid zone, and greater central macular thickness (CMT) than in the responsive group. Worse initial BCVA, presence of intraretinal fluid (IRF) and external limiting membrane disruption at the third month after treatment was associated with poorer final BCVA (p = 0.021, 0.014, and 0.044, respectively). Cases receiving three consecutive loading injections indicated better final BCVA (p = 0.008). Patients receiving aflibercept required fewer injections than those receiving ranibizumab (p = 0.005).

Conclusions: Baseline predictors of ME recurrence included SRF presence, outer retinal layer disruptions, and greater CMT. Baseline vision, IRF at 3rd month, and the number of consecutive loading injection were correlated with visual outcomes.

Keywords: Branch retinal vein occlusion; Fluorescein angiography; Intravitreal injection of anti-vascular endothelial growth factor antibody; Macular edema; Optical coherence tomography.

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflict of interest: The authors declare no competing interests. Consent to participate: Written informed consent was obtained from the participants. Consent to publish: The authors affirm that human research participants provided informed consent for publication of the images in Fig. 2a–l. Ethics approval: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Institutional Review Board of the hospital (CGH-P112040).

Similar articles

See all similar articles

References

    1. Rogers S, McIntosh RL, Cheung N, Lim L, Wang JJ, Mitchell P et al (2010) The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology 117:313-319.e1. https://doi.org/10.1016/j.ophtha.2009.07.017 - DOI - PubMed
    1. Zhou JQ, Xu L, Wang S, Wang YX, You QS, Tu Y et al (2013) The 10-year incidence and risk factors of retinal vein occlusion: the Beijing eye study. Ophthalmology 120:803–808. https://doi.org/10.1016/j.ophtha.2012.09.033 - DOI - PubMed
    1. Hayreh SS, Rojas P, Podhajsky P, Montague P, Woolson RF (1983) Ocular neovascularization with retinal vascular occlusion-III. Incidence of ocular neovascularization with retinal vein occlusion. Ophthalmology 90:488–506. https://doi.org/10.1016/s0161-6420(83)34542-5 - DOI - PubMed
    1. Li J, Paulus YM, Shuai Y, Fang W, Liu Q, Yuan S (2017) New developments in the classification, pathogenesis, risk factors, natural history, and treatment of branch retinal vein occlusion. J Ophthalmol 2017:4936924. https://doi.org/10.1155/2017/4936924 - DOI - PubMed - PMC
    1. Noma H, Funatsu H, Yamasaki M, Tsukamoto H, Mimura T, Sone T et al (2008) Aqueous humour levels of cytokines are correlated to vitreous levels and severity of macular oedema in branch retinal vein occlusion. Eye (Lond) 22:42–48. https://doi.org/10.1038/sj.eye.6702498 - DOI - PubMed

MeSH terms

LinkOut - more resources